BPC 157 was used in the same regular regimens (10 g or 10 ng/kg, per-orally/intragastrically), shown to be effective in all BPC 157 studies (5, 9)
This reprogramming involves the downregulation of genes associated with proinflammatory responses and resistance to tissue invasion, along with the upregulation of genes that enhance cell proliferation, promote tolerance, and support tissue invasion (Sun et al., 2023)
Representative participants: Kite Pharma (Gilead Sciences), Novartis Gene Therapies, bluebird bio, Spark Therapeutics (Roche), Sarepta Therapeutics, and uniQure N.V
Research indicates that collagen supplementation may help reduce joint stiffness and improve mobility, particularly in active individuals